Person: Martínez De La Casa Fernández-Borrella, José María
Loading...
First Name
José María
Last Name
Martínez De La Casa Fernández-Borrella
Affiliation
Universidad Complutense de Madrid
Faculty / Institute
Óptica y Optometría
Department
Inmunología, Oftalmología y ORL
Area
Oftalmología
Identifiers
5 results
Search Results
Now showing 1 - 5 of 5
Item Contrast sensitivity and disability glare in patients with dry eye(Acta Ophthalmologica Scandinavica, 2006) Puell Marín, María Cinta; Benítez Del Castillo Sánchez, José Manuel; Martínez De La Casa Fernández-Borrella, José María; Sánchez Ramos, Celia; Aladro Vico, Eva; Pérez Carrasco, María Jesús; Pedraza Aranda, Constanza; Hierro Zarzuelo, Almudena, delPurpose: To evaluate contrast sensitivity and disability glare in patients with dry eye using the Contrast Glaretester 1000. Methods: Contrast sensitivity and disability glare were determined in 33 eyes of 33 patients with dry eye and 30 eyes of 30 healthy control subjects for six target sizes with a visual angle of 6.3-0.7 degrees using the Contrast Glaretester 1000, whose working mechanism is similar to that of the conventional perimetry instrument. Results: Contrast sensitivity was significantly worse in dry eye group when viewing all target sizes (reduction of 0.10-0.25 log contrast units, p < 0.01) except at 6.3 degrees. In the presence of glare, differences in log contrast sensitivity between the groups (0.10-0.25 units) were significant (p < 0.01) for all target sizes, with the dry eye group showing worse results. The reduction in contrast sensitivity induced by glare (disability glare) was significantly worse in the dry eye group versus the control group but only for the 2.5-degree size target, where 0.14 log contrast units were lost. Conclusions: Contrast sensitivity with and without glare was significantly reduced in patients with dry eye compared with control subjects, but the number of log contrast units lost with glare (disability glare) was similar in the two groups, except for the 2.5-degree size target.Item High-frequency ultrasound biomicroscopy of silicone posterior chamber phakic intraocular lens for hyperopia(Journal of Cataract and Refractive Surgery, 2003) García Feijoo, Julián; Hernández Matamoros, J.L; Castillo Gómez, Alfredo; Lázaro, C; Méndez Hernández, Carmen Dora; Martín, T; Martínez De La Casa Fernández-Borrella, José María; García Sánchez, JuliánPurpose: To study the intraocular position and anatomic relationships of the PRL-III phakic refractive lens (PRL), a posterior chamber phakic intraocular lens (PCP IOL), in cases of hyperopia using ultrasound biomicroscopy (UBM). Setting: Centro Oftalmológico Real Vision, Madrid, Spain, and Instituto de Investigaciones Oftalmológicas Ramón Castroviejo, Universidad Complutense, Madrid, Spain. Methods: Eleven phakic hyperopic eyes of 6 patients who had PRL implantation were examined by UBM 1 month after surgery. The PRL position, PRL-crystalline lens peripheral distance, and central distance between the corneal endothelium and the PRL were measured. Results: Eight eyes had both haptics on the zonule, 2 had 1 haptic in the sulcus and 1 on the zonule, and 1 had 1 haptic in the sulcus and the other in the ciliary body. The mean PCP IOL-crystalline lens peripheral distance in the minor axis was 239.7 μm ± 179.4 (SD) and the mean PCP IOL-endothelium central distance, 2146.98 ± 219.6 μm. Contact between the PCP IOL and crystalline lens was observed in 1 eye. Conclusions: In this study of hyperopic eyes, the PRL was located on the zonule in most cases. However, the location of the haptics in the sulcus and contact between the PCP IOL and the crystalline lens that occurred in some cases suggest further study of possible long-term complications is needed. © 2003 ASCRS and ESCRS.Item Circadian IOP-lowering efficacy of travoprost 0.004% ophthalmic solution compared to latanoprost 0.005%(Current Medical Research and Opinion, 2006) García Feijoo, Julián; Martínez De La Casa Fernández-Borrella, José María; Castillo, A; Méndez Hernández, Carmen Dora; Fernández Vidal, Ana María; García Sánchez, JuliánPurpose: The primary objective of this study was to determine the intraocular pressure- (IOP) lowering efficacy over two consecutive 24-h periods of travoprost 0.004% ophthalmic solution (Travatan†) compared to latanoprost 0.005% (Xalatan‡) dosed once daily in patients with primary open-angle glaucoma or ocular hypertension. Methods: This was a double-masked trial conducted at the Hospital Clinico San Carlos, Madrid, Spain. The primary objective of this study was to determine the IOP lowering efficacy of travoprost and latanoprost. During the eligibility visit, patients' IOP was measured throughout two consecutive 24-h periods every 4 h. Patients were then randomized to travoprost or latanoprost (one drop at 8 p.m. daily for 2 weeks). Sixty-two patients were randomized (travoprost n = 32; latanoprost n = 30). IOP was measured at week 2 every 4 h throughout two 24-h periods. All measurements were taken in both supine and sitting positions with the aid of Perkins applanation tonometry. Limitations of the study include a small sample size (due to the difficulty in recruiting patients in a study of this type) which enrolled only Caucasian patients and a short study duration. However, with 25 subjects per group, there was at least 90% power to detect a mean IOP change from baseline of 2.9 mmHg and 80% power to detect a difference of 2.5 mmHg between treatments. Results: Patients on travoprost therapy showed lower mean IOP levels than those on latanoprost. This difference was statistically significant (p < 0.05) at 12, 16, 20, 24, 36, 40, and 48 h after the last dose for the supine position. The mean IOPs in the supine position throughout the first and the second 24-h period of the week 2 visit as well as for the 48-h visit were statistically lower (p < 0.05) for the travoprost group. Adverse events were mild and included hyperemia and corneal staining. Travoprost and latanoprost were both well tolerated. Conclusion: Mean IOP values were significantly lower for patients on travoprost for the majority of time points in the supine position. © 2006 Librapharm Limited.Item Ocular response analyzer versus Goldmann applanation tonometry for intraocular pressure measurements(Investigative Ophthalmology and Visual Science, 2006) Martínez De La Casa Fernández-Borrella, José María; García Feijoo, Julián; Fernández Vidal, Ana María; Méndez Hernández, Carmen Dora; García Sánchez, JuliánPURPOSE. To establish correlations between intraocular pressure (IOP) measurements obtained with the ocular response analyzer (ORA) and the Goldmann applanation tonometer (GAT). The effects of central corneal thickness on the measures obtained were also examined. METHODS. This was a cross-sectional study. IOP was determined in 48 eyes of 48 patients with glaucoma In all patients, central corneal thickness (CCT) was measured by ultrasound pachymetry. RESULTS. ORA readings were consistently higher than GAT measurements (Goldmann-correlated IOP -IOP GAT mean difference, 7.2 ± 3.5 mm Hg; corneal-compensated IOP - IOP GAT mean difference, 8.3 ± 4.0 mm Hg) However, differences were not constant and increased with increasing IOP GAT readings, both with respect to Goldmann-correlated IOP (slope = 0.623, P < 0.0001) and corneal-compensated IOP (slope = 0.538, P < 0.0001). Both pressure measurements provided by the ORA showed significant correlation with CCT (CCT versus Goldmann-correlated IOP: r = 0.460, P = 0.001; CCT versus corneal-compensated IOP: r = 0.442, P = 0.001). No significant effects of corneal curvature or refraction on any of the pressures were observed. CONCLUSIONS. The ORA significantly overestimates IOP compared with the GAT. Differences between both sets of measures increase as the GAT-determined IOP increases. ORA readings seem to be affected by central corneal thickness. Copyright © Association for Research in Vision and Ophthalmology.Item Concomitant administration of travoprost and brinzolamide versus fixed latanoprost/timolol combined therapy: Three-month comparison of efficacy and safety(Current Medical Research and Opinion, 2004) Martínez De La Casa Fernández-Borrella, José María; Castillo, A; García Feijoo, Julián; Méndez Hernández, Carmen Dora; Fernández Vidal, Ana María; García Sánchez, JuliánPurpose: To compare the efficacy and safety of the concomitant administration of travoprost 0.004% once daily and brinzolamide 0.1% twice daily with those of a fixed combination of latanoprost 0.005%/timolol 0.5% once daily. Research, design and methods: Forty-four patients with primary open-angle glaucoma or ocular hypertension with elevated IOP insufficiently responsive to monotherapy were randomly assigned to one of the two treatment groups: concomitant administration of travoprost 0.004% once daily and brinzolamide 0.1% twice daily (TB group: 22 patients) or latanoprost 0.005% plus timolol 0.5% once daily (LT group: 22 patients). Visits were undertaken at screening (current ocular hypotensive therapy was discontinued), baseline (randomization), and after 2 weeks, 1 month, 2 months and 3 months of therapy. Main outcome measures: IOP was determined at 9 a.m., 12 p.m. and 4 p.m. at each study visit, and diurnal IOP was calculated as the mean of these recordings. Adverse events were recorded at each visit. Results: IOP at the baseline visit was similar in both groups. Overall mean IOP was significantly lower in the TB as compared to the LT group after 1 month, 2 month and 3 month follow-up; only 9 a.m. measurements were significantly different, reaching a maximum difference (16.9 ± 0.9 mmHg vs 18.4 ± 1.8 mmHg, p < 0.001) at the 3 month check. The percentage of respondent (IOP decrease ≥ 30%) was higher in the TB group. Both treatments were well tolerated and there were no cases of withdrawal from treatment. Conclusions: Travoprost 0.004% and brinzolamide 0.1% concomitant therapy showed a greater efficacy than the fixed latanoprost 0.005%/timolol 0.5% combination in terms of absolute IOP decreases. Travoprost/brinzolamide therapy also offered the advantages of a greater percentage of responders.